Welcome to our dedicated page for Entero Therapeutics news (Ticker: ENTO), a resource for investors and traders seeking the latest updates and insights on Entero Therapeutics stock.
Entero Therapeutics Inc., now GridAI Technologies Corp., reports developments tied to its completed acquisition of Grid AI and its change from a gastrointestinal therapeutics issuer to an AI-driven energy-infrastructure software company. Grid AI operates as a wholly owned subsidiary with a grid-edge software and controls platform for utilities, retail energy providers and large power users managing load and distributed energy resources, including battery energy storage systems.
Company news has centered on the name and ticker transition, Nasdaq compliance matters, Grid AI platform commercialization, data-center power orchestration, and legacy biopharmaceutical disclosures involving Adrulipase, a recombinant lipase enzyme program for exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis.
Entero Therapeutics (NASDAQ:ENTO) will change its name to GridAI Technologies Corp. and its ticker to GRDX, effective at 12:01 AM/ET on December 1, 2025. The change follows the Company's acquisition of 100% of GRID AI Corp, a grid-edge AI software and controls platform for utilities, retail energy providers, and large power users. The Company's common stock will begin trading on the Nasdaq Capital Market under the new name and symbol on December 1, 2025. The company said the name and ticker changes do not alter its legal structure, operations, or financial reporting, and shareholders are not required to take any action.
Entero Therapeutics (NASDAQ:ENTO) announced that subsidiary Grid AI executed a Letter of Intent on November 19, 2025 to deploy its power-cluster optimization and orchestration platform with a stealth-mode hyperscaler AI data-center developer.
The LOI covers an initial Texas campus in the ERCOT market with expected Grid AI revenue beginning Q3 2026, roughly $8 million in 2027 and scaling to over $50 million in 2029. A definitive commercial agreement is expected in early Q1 2026. The multi-phase partnership will validate optimization, integrate behind-the-meter generation and storage, and deliver a unified technoeconomic model and dispatch/optimization engine for multi-hundred-megawatt AI campuses.
Entero Therapeutics (NASDAQ:ENTO) said its subsidiary Grid AI is finalizing a U.S.-based leadership team to accelerate a major U.S. expansion of its AI-ready digital infrastructure and orchestration technology.
The company expects to name a U.S. CEO and Executive Chairman soon and cites leadership with public-markets experience in demand-response and energy-flexibility. Grid AI highlights industry demand signals including $60B of new AI-data-center projects announced in the past 90 days, AMD's projection of a $1T data-center market by 2030, and a need for >2,000 new data centers worldwide.
Entero says it has invested $50M since 2019 to develop the platform and will provide further updates on appointments and U.S. expansion in the coming weeks.
Entero (NASDAQ:ENTO) announced a Letter of Intent to integrate LV Grid's engineering team and IP into its Grid AI subsidiary to expand into the hyperscaler AI data-center energy-orchestration market.
The combined team will develop an AI Data Center Controls division and deliver a digital-dispatch and campus-optimization engine, starting with a flagship AI data-center energy park in Texas. Management highlighted potential recurring software revenues and optimization fees from hyperscaler customers.
Entero cited Goldman Sachs estimates of ~50 GW incremental hyperscale power demand by 2028–2030, $300–600 billion in build-out costs, and a $10–20 billion addressable market for next-generation optimization platforms.
Entero Therapeutics (NASDAQ:ENTO) announced on October 30, 2025 that it acquired 100% of Grid AI Corp., has made Grid AI a wholly owned subsidiary, and has regained compliance with Nasdaq Listing Rule 5550(b)(1). The company describes its platform as positioned at the intersection of AI, hyperscale data centers, power grids and global infrastructure to pursue grid-edge orchestration and AI-driven infrastructure optimization.
The release also notes forward-looking statements and specifically references the need to obtain shareholder approval for common stock underlying preferred stock issued in the acquisition and uncertainty about future results.
Entero Therapeutics (NASDAQ:ENTO) launched Grid AI Corp. on October 16, 2025 to coordinate AI data center compute with electric grids. The company says rising AI demand will push global data center electricity beyond 1,000 TWh and that AI workloads account for over 30% of that growth, requiring more than $1 trillion in new energy and digital infrastructure investment.
Grid AI's platform claims to orchestrate and dispatch flexible data center loads in real time, unlocking stranded capacity, shortening interconnection timelines, and enabling participation in demand-response and ancillary markets. Analysts cited estimate flexible capacity (5–10%) could free >100 GW, accelerate deployments by up to 24 months, and create a $150–$200 billion annual addressable market for software and controls.
Entero Therapeutics (NASDAQ:ENTO) has announced a transformative acquisition of GRID AI Corp, positioning itself in the rapidly growing AI energy-infrastructure market. GRID AI's platform utilizes AI and machine learning to manage distributed energy resources and balance power supply and demand in real-time.
The deal structure gives GRID AI shareholders 82.5% ownership of ENTO's fully diluted common stock, while existing ENTO shareholders retain 17.5%. GRID AI's technology addresses the surging power demands from AI data centers, with Goldman Sachs projecting global data-center power demand to increase ~50% by 2027 and up to 165% by 2030 versus 2023 levels.
The acquisition leverages over $50 million invested in GRID AI since 2019, targeting a market expected to see AI infrastructure investments exceeding $2.8 trillion by 2029.
Entero Therapeutics (NASDAQ: ENTO) has announced the acquisition of GRID AI Corp, a grid-edge AI platform company, marking a strategic pivot into the AI energy infrastructure market. GRID AI's platform, which has received over $50 million in investment since 2019, specializes in Dynamic Load Shaping and Aggregation Management for behind-the-meter energy assets.
The transaction structure will result in GRID AI shareholders owning 82.5% of ENTO's fully diluted common stock, while existing ENTO shareholders will retain 17.5%. The deal includes board restructuring, with GRID AI shareholders initially appointing two directors and eventually controlling five of seven board seats.
This strategic acquisition positions ENTO in a high-growth market, as Goldman Sachs projects global data-center power demand to increase by ~50% by 2027 and up to 165% by 2030 versus 2023 levels, driven by AI infrastructure expansion.
Entero Therapeutics (NASDAQ: ENTO), a clinical-stage biopharmaceutical company focused on GI disease therapies, announced a 1-for-3 reverse stock split effective August 18, 2025. The split will reduce outstanding shares from 4.77 million to approximately 1.59 million.
The reverse split aims to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. Stockholders will receive cash in lieu of fractional shares. The company's interim CEO emphasized that maintaining Nasdaq listing visibility is crucial for enhancing shareholder value.
Entero Therapeutics (NASDAQ: ENTO), a clinical-stage biopharmaceutical company focused on GI diseases, has secured a $3 million private placement through the sale of pre-funded and common warrants. The offering includes 4,878,841 pre-funded warrants and 9,757,682 common warrants, with a combined purchase price of $0.6149 for one pre-funded warrant and two common warrants.
The pre-funded warrants have an exercise price of $0.00001 and are immediately exercisable. The common warrants, exercisable at $0.3649 per share, have a 5-year term. The company will receive $1 million at closing and the remaining $2 million upon registration statement effectiveness. The transaction is expected to close around August 11, 2025.